Early clinical experience with subcutaneous GR43175 in acute migraine: an overview

Research output: Contribution to journalJournal articleResearchpeer-review

In six European clinics 111 migraine patients were treated in a series of open dose-ranging studies with subcutaneous injections of 1 to 4 mg GR43175, a novel 5-HT 1-like receptor agonist. Response rates after 20-30 min were dose related and rose from 33% with 1 mg to 96% with 4 mg GR43175. Side effects were minor and transient. These promising results warrant confirmation in placebo-controlled double-blind trials. Migraine, treatment, 5-HT agonist, open studies.

Original languageEnglish
JournalCephalalgia : an international journal of headache
Volume9 Suppl 9
Pages (from-to)73-7
Number of pages5
Publication statusPublished - 1989

    Research areas

  • Adolescent, Adult, Aged, Dose-Response Relationship, Drug, Female, Humans, Indoles, Injections, Subcutaneous, Male, Middle Aged, Migraine Disorders, Sulfonamides, Sumatriptan

ID: 128984851